Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
featured
RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

  • 230 views
  • 08 Nov, 2020
  • 1 location
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the

  • 5 views
  • 25 May, 2021
  • 34 locations
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced

  • 0 views
  • 12 Sep, 2021
  • 75 locations
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing

aromatase inhibitor
paclitaxel
HER2
stage iii breast cancer
cyclophosphamide
  • 33 views
  • 07 Nov, 2020
  • 1 location
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low

  • 37 views
  • 28 Jun, 2021
  • 259 locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in

atezolizumab
HER2
cyclophosphamide
sentinel node
estrogen
  • 17 views
  • 24 Jan, 2021
  • 51 locations
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

randomised to receive either docetaxel 100 mg/m2 i.v. plus trastuzumab 6 mg/kg (8 mg/kg loading dose) q 3 weeks or vinorelbine 30 or 35 mg/m2 days 1+8 plus trastuzumab 6 mg/kg (8 mg/kg loading dose

trastuzumab
docetaxel
her2/neu-positive breast cancer
stage iv breast cancer
vinorelbine
  • 32 views
  • 07 Nov, 2020
  • 1 location
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated

metastasis
platelet count
urine test
olaparib
HER2
  • 7 views
  • 27 Jan, 2021
  • 27 locations
Efficacy and Safety Study of Trastuzumab Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer

To compare the efficacy in terms of the pathological complete response rate (pCR) to preoperative administration of qw or q3w Paclitaxel, Carboplatin and Trastuzumab (PCH)

cish
advanced breast cancer
chromogenic in situ hybridization
core needle biopsy
invasive breast cancer
  • 0 views
  • 08 Nov, 2020